China Kanghui Holdings (NYSE:

) has outperformed the S&P since its IPO in August (+20% vs. +3.4%) showing healthy investor interest in the Chinese orthopedics market, according to Piper Jaffray. KH separates itself from its competitors by implementing a well-assembled management team and its access to technology, and KH is expected to post an EPS CAGR of 22% from 2009-2015, driven by its new product launches and market share gains, Piper Jaffray reports. Piper Jaffray initiates with a Neutral rating and $14 price target. China Kanghui Holdings closed Friday at $12.33.